geranylgeranylacetone and Ventricular-Dysfunction--Left

geranylgeranylacetone has been researched along with Ventricular-Dysfunction--Left* in 1 studies

Trials

1 trial(s) available for geranylgeranylacetone and Ventricular-Dysfunction--Left

ArticleYear
Geranylgeranylacetone reduces cardiomyocyte stiffness and attenuates diastolic dysfunction in a rat model of cardiometabolic syndrome.
    Physiological reports, 2023, Volume: 11, Issue:22

    Titin-dependent stiffening of cardiomyocytes is a significant contributor to left ventricular (LV) diastolic dysfunction in heart failure with preserved LV ejection fraction (HFpEF). Small heat shock proteins (HSPs), such as HSPB5 and HSPB1, protect titin and administration of HSPB5 in vitro lowers cardiomyocyte stiffness in pressure-overload hypertrophy. In humans, oral treatment with geranylgeranylacetone (GGA) increases myocardial HSP expression, but the functional implications are unknown. Our objective was to investigate whether oral GGA treatment lowers cardiomyocyte stiffness and attenuates LV diastolic dysfunction in a rat model of the cardiometabolic syndrome. Twenty-one-week-old male lean (n = 10) and obese (n = 20) ZSF1 rats were studied, and obese rats were randomized to receive GGA (200 mg/kg/day) or vehicle by oral gavage for 4 weeks. Echocardiography and cardiac catheterization were performed before sacrifice at 25 weeks of age. Titin-based stiffness (F

    Topics: Animals; Connectin; Heart Failure; Humans; Male; Metabolic Syndrome; Myocytes, Cardiac; Obesity; Rats; Stroke Volume; Ventricular Dysfunction, Left

2023